Form 8-K

8-K — Alzamend Neuro, Inc.

Accession: 0001214659-26-012132

Filed: 2026-09-29

Period: 2026-09-29

CIK: 0001677077

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — x9282618k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex99_1.htm)

GRAPHIC (slide_001.jpg)

GRAPHIC (slide_002.jpg)

GRAPHIC (slide_003.jpg)

GRAPHIC (slide_004.jpg)

GRAPHIC (slide_005.jpg)

GRAPHIC (slide_006.jpg)

GRAPHIC (slide_007.jpg)

GRAPHIC (slide_008.jpg)

GRAPHIC (slide_009.jpg)

GRAPHIC (slide_010.jpg)

GRAPHIC (slide_011.jpg)

GRAPHIC (slide_012.jpg)

GRAPHIC (slide_013.jpg)

GRAPHIC (slide_014.jpg)

GRAPHIC (slide_015.jpg)

GRAPHIC (slide_016.jpg)

GRAPHIC (slide_017.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: x9282618k.htm · Sequence: 1

false

0001677077

2026-09-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

___________________________________________________________________

Date of Report (Date of earliest event reported): September

29, 2026

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40483

81-1822909

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

3480 Peachtree Road NE, Second Floor, Suite

103, Atlanta, GA 30326

(Address of principal executive offices) (Zip Code)

(844) 722-6333

(Registrant's telephone number, including area

code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

ALZN

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On September 29, 2026, Dr.

Ovidiu C. Andronesi, principal investigator on Alzamend Neuro, Inc.’s Phase 1/2A Clinical Trial, Director of Multinuclear MRI, Martinos

Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, and Associate Professor of Radiology at Harvard

Medical School, will presented at the International Society for MR Radiographers & Technologists (ISMRT) Conference. A copy of the

presentation, which is furnished herewith as Exhibit 99.1, is incorporated by reference herein.

In accordance with General

Instruction B.2 of Form 8-K, the information under this item and Exhibit 99.1 shall not be deemed filed for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing

under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report

will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of

Regulation FD.

The Securities and Exchange

Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects

of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements,

which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which

involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking

statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,”

“will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual

results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely

unduly on forward-looking statements when evaluating the information presented within.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

99.1

ISMRT Presentation

101

Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALZAMEND NEURO, INC.

Dated: September 29, 2026

s/ David J. Katzoff

David J. Katzoff

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex99_1.htm · Sequence: 2

Exhibit 99.1

DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqing Deng, Melanie Brown, Sara Farina, Paul Weiser, Tan - Hanh Pham, Nathaniel Mercaldo, Donald Reitberg, Eve Del Rio, Michael Henry, Kraig Roajphlastien, Stephan Jackman, Kelli S. Devitte - McKee, Alison McManus, Jessica Gerber, Steven Arnold, Hope Taft, Susie Huang, Bruce R. Rosen ISMRM Workshop Advances in X - Nuclei MR, 29 Sept 2026

Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation : • Company Name: Alzamend Neuro Inc • Type of Relationship: Sponsored research funding Declaration of Financial Interests or Relationships ISMRM Workshop Series

3 • Lithium is the gold standard treatment for bipolar disorder , and often used in major depressive disorder, schizophrenia or Alzheimer’s disease. • Clinical utility is constrained by a narrow therapeutic window for inorganic lithium salts (Li 2 CO 3 ) which need careful monitoring to manage renal, thyroid, and other systemic toxicity risks. • In this clinical trial we investigated the brain pharmacokinetics of AL001, a novel organic co - crystal containing lithium salicylate/L - proline designed for better brain delivery with less systemic exposure than inorganic salts. LITHIUM TREATMENT

AL001 4 4 AL001 = co - crystal of Lithium salicylate + L - proline (LISPRO crystal) Pre - clinical studies in mice indicated a better PK profile for lithium salicylate Smith A et al, RSC Adv., 2014, 4, 12362 – 12365

5 CLINICAL TRIAL DESIGN Baseline MRI (1x) Baseline Plasma (1x) Period1 MRI (7x) Period1 Plasma (28x) Period2 MRI (7x) Period2 Plasma (28x) 30 Participants: • 6 Healthy • 6 Bipolar • 6 Major Depression • 6 Alzheimer • 6 PTSD Phase 1/2a design: • 2 treatments • 2 periods • randomized • longitudinal • cross - over 14 days 14 days All participants receive both treatments, AL001 and Li 2 CO 3 ClinicalTrials.gov/NCT06921590

6 LITHIUM IMAGING • MR Scanner: 7T Terra.X (Siemens Healthineers) • Dual - tuned coil: 7Li/1H 1Tx/1Tx - 16Rx/16Rx (Tesla Dynamics Coil) • Pulse sequence: 3D radial balanced SSFP (3D bSSFP) • Image reconstruction: Regridding + density compensation (ICE on - line) • Image processing: Super - resolution upsampling + Absolute Quantification + MNI + PK modeling 3D radial bSSFP: • TR/TE = 10ms/5ms, • FA = 22  , • Voxel = 8 cm 3 (20 mm iso) • Spokes = 400, • NA = 375, • TA = 25:02 min:s Image processing: • Freesurfer + FSL + MINC + Python • Pipeline compliant with CFR 2.11 regulations for FDA submission

7 IMAGE PROCESSING PIPELINE

8 IMAGE PROCESSING PIPELINE Xianqi Li et al, Radiology 2020, 294, 589 - 597 ܠ ො ൌ ܽݎ݃ ‹ ሼ ܠ ܡ െ ܪ ሺ ܠ ሻ ଶ ൅ ࣅ ܴ ሺ ܠ ሻ ሽ ܴ ܠ ൌ ෍ ܠ ܞ െ ෍ ܟ ሺ ܞ ǡ ܝ ሻ ܠ ܝ ܝ א π ሺ ܞ ሻ ଶ ܞ Low - res MRSI High - res MRI Super - res MRSI Super - resolution: regularized patch based feature nonlocal means Absolute Quantification: bSSFP relaxation correction with finite RF pulse duration Non - convex optimization Bieri et al, MRM, 2009, 62:1232 Bernstein et al, Handbook of MRI Pulse Sequences

9 PHANTOM VALIDATION Lithium image spatial resolution of 3D radial bSSFP

10 PHANTOM VALIDATION Absolute Quantification of Li concentration from bSSFP images Variability: test - retest triplicates Linearity and lower limit of quantitation

11 Rating of Li Image Quality by Radiologists Gwet’s Agreement Coefficient Agreement Analysis Landis - Koch Benchmark Label Estimate (95%CI) Substantial 0.73 (0.66, 0.80) Primary Analysis - assuming complete independence Moderate - Fair 0.61 (0.28, 0.83) Sensitivity Analysis - not assuming complete independence Very Poor (1) Poor (2) Adequate (3) Good (4) Excellent (5) Li image # 1 - 96 92% of images scored Excellent - Adequate

12 Lithium Brain Concentration Baseline AL001 Li 2 CO 3 1 0 mM 1 0 mM 1 0 mM [Li] in GM and WM [mM]

13 Voxel - wise General Linear Model [Li] Treatment - Baseline 2 1.3 - Log 10 (p) AL001 - Baseline Li 2 CO 3 - Baseline 2 1.3 - Log 10 (p)

14 PK analysis – non - compartmental model [Li] plasma [Li] white matter [Li] gray matter AUC AL001 = 53873 ( hr *ng/mL) AUC Li 2 CO 3 = 51427 ( hr *ng/mL) AUC AL001 = 32370.77 ( hr *ng/mL) AUC Li 2 CO 3 = 29309.12 ( hr *ng/mL) ) AUC AL001 = 37347.73 ( hr *ng/mL) AUC Li 2 CO 3 = 33581.70 ( hr *ng/mL) )

15 PK analysis – two - compartments model K1 (ml/cm 3 /min) 3 0 ml/cm 3 /min

Summary 16 » 7 Tesla provides higher SNR for lithium imaging and allows quantification of lithium concentration in the brain over the PK relevant range ( 0 . 1 - 1 mM ; 694 - 6941 ng/g) with anatomical spatial resolution . » Brain region analysis indicate a trend for slightly higher Li concentration after AL 001 (geometric mean 4020 . 64 ng/g, 64 % CV) compared to Li 2 CO 3 ( geometric mean 3476 . 94 ng/g, 57 % CV), with slightly larger values in white matter than gray matter . » Voxel - wise general linear model indicate a trend for higher Li concentration in the gray matter after AL 001 compared to Li 2 CO 3 . » Non - compartment PK modelling indicate a trend for slightly higher AUC after AL 001 ( geometric mean 62230 h  ng /g, 26 % CV) compared to Li 2 CO 3 ( geometric mean 59715 h  ng /g, 25 % CV) . » Two compartment PK modelling indicate higher plasma to brain transfer rate (K 1 ) in the white matter than gray matter for AL 001 . » Differences between AL 001 and Li 2 CO 3 are not statistically significant , in line with the small sample size . The observed trends in the healthy cohort generate hypothesis that will be tested in subsequent patient cohorts (bipolar, major depression, Alzheimer and PTSD) .

Acknowledgements MGH, Department of Radiology Martinos Biomedical Imaging Center: Katherine Maina Paul Weiser Tan - Hanh Pham Nathaniel Mercaldo May Aon Shuqing Deng Melanie Brown Sarah Farina Hope Taft Susie Huang Bruce Rosen MGH, Department of Psychiatry: Steven Arnold Michael Henry MGH, Clinical Translation Research Unit Jessica Gerber Kelli S. Devitte - McKee, Alison McManus Alzamend Neuro Inc Stephan Jackman Donald Reitberg, Eve Del Rio, Kraig Roajphlastien, QMENTA Oscar Pena Evie Neylon Kire Trivodaliev Human Predictions William Denney Paul Weiser Shuqing Deng Katy Maina May Aon Melanie Brown Hanh Pham

GRAPHIC

Filename: slide_001.jpg · Sequence: 6

Binary file (75006 bytes)

Download slide_001.jpg

GRAPHIC

Filename: slide_002.jpg · Sequence: 7

Binary file (66738 bytes)

Download slide_002.jpg

GRAPHIC

Filename: slide_003.jpg · Sequence: 8

Binary file (90719 bytes)

Download slide_003.jpg

GRAPHIC

Filename: slide_004.jpg · Sequence: 9

Binary file (56066 bytes)

Download slide_004.jpg

GRAPHIC

Filename: slide_005.jpg · Sequence: 10

Binary file (91791 bytes)

Download slide_005.jpg

GRAPHIC

Filename: slide_006.jpg · Sequence: 11

Binary file (62362 bytes)

Download slide_006.jpg

GRAPHIC

Filename: slide_007.jpg · Sequence: 12

Binary file (84295 bytes)

Download slide_007.jpg

GRAPHIC

Filename: slide_008.jpg · Sequence: 13

Binary file (78533 bytes)

Download slide_008.jpg

GRAPHIC

Filename: slide_009.jpg · Sequence: 14

Binary file (52208 bytes)

Download slide_009.jpg

GRAPHIC

Filename: slide_010.jpg · Sequence: 15

Binary file (62673 bytes)

Download slide_010.jpg

GRAPHIC

Filename: slide_011.jpg · Sequence: 16

Binary file (88361 bytes)

Download slide_011.jpg

GRAPHIC

Filename: slide_012.jpg · Sequence: 17

Binary file (64845 bytes)

Download slide_012.jpg

GRAPHIC

Filename: slide_013.jpg · Sequence: 18

Binary file (61627 bytes)

Download slide_013.jpg

GRAPHIC

Filename: slide_014.jpg · Sequence: 19

Binary file (65706 bytes)

Download slide_014.jpg

GRAPHIC

Filename: slide_015.jpg · Sequence: 20

Binary file (56195 bytes)

Download slide_015.jpg

GRAPHIC

Filename: slide_016.jpg · Sequence: 21

Binary file (109694 bytes)

Download slide_016.jpg

GRAPHIC

Filename: slide_017.jpg · Sequence: 22

Binary file (76769 bytes)

Download slide_017.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 24

v3.26.3

Cover

Sep. 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 29, 2026

Entity File Number

001-40483

Entity Registrant Name

ALZAMEND NEURO, INC.

Entity Central Index Key

0001677077

Entity Tax Identification Number

81-1822909

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3480 Peachtree Road NE

Entity Address, Address Line Two

Second Floor

Entity Address, Address Line Three

Suite

103

Entity Address, City or Town

Atlanta

Entity Address, State or Province

Entity Address, Postal Zip Code

30326

City Area Code

(844)

Local Phone Number

722-6333

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value

Trading Symbol

ALZN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration